Question 1

What is the apelin/APJ system and why is it important?

Accepted Answer

The apelin/APJ system is an endogenous peptide signaling axis consisting of the apelin peptide family and their receptor, APJ (also called APLNR). This system plays a crucial role in cardiovascular homeostasis, acting as a natural counterbalance to the renin-angiotensin-aldosterone system (RAAS). Where angiotensin II promotes vasoconstriction, hypertrophy, and fluid retention, apelin promotes vasodilation, beneficial cardiac contractility, and water excretion. The discovery that apelin levels are depleted in heart failure has made this system an attractive therapeutic target.

Question 2

What forms of apelin exist and which is most potent?

Accepted Answer

Several biologically active apelin isoforms are produced from the preproapelin precursor: apelin-36, apelin-17, apelin-13, and [Pyr1]apelin-13 (pyroglutamyl-modified). Of these, [Pyr1]apelin-13 is considered the most potent form in cardiovascular assays and is the predominant circulating form. It is also the most commonly used form in research. The pyroglutamate modification protects the N-terminus from aminopeptidase degradation, providing slightly improved stability compared to unmodified apelin-13.

Question 3

Why is apelin being studied for heart failure?

Accepted Answer

Apelin is of particular interest in heart failure for several reasons: (1) circulating apelin levels are significantly reduced in heart failure patients and correlate inversely with disease severity; (2) apelin increases cardiac contractility without promoting pathological hypertrophy, unlike catecholamines; (3) it reduces preload and afterload through vasodilation and diuresis; and (4) in preclinical heart failure models, exogenous apelin administration improves cardiac output, exercise capacity, and survival. Early-phase human studies have shown that apelin infusion acutely improves cardiac index in heart failure patients.

Question 4

What is the main limitation of native apelin as a therapeutic?

Accepted Answer

The most significant limitation is its extremely short half-life — approximately 5 minutes for intravenous apelin-13. Native apelin is rapidly degraded by angiotensin-converting enzyme 2 (ACE2) and other circulating peptidases. This makes sustained therapeutic effects impractical with native apelin and has driven development of stabilized analogs (such as apelin analogs with non-natural amino acids or PEGylation) that resist enzymatic degradation while retaining APJ receptor activity.

Question 5

How does apelin interact with the renin-angiotensin system?

Accepted Answer

Apelin and angiotensin II have largely opposing cardiovascular effects, and their receptors (APJ and AT1R) can form heterodimers that modify each other's signaling. Apelin opposes angiotensin II-mediated vasoconstriction, aldosterone secretion, and cardiac hypertrophy. Interestingly, ACE2 — the enzyme that degrades angiotensin II into the protective angiotensin-(1-7) — also cleaves apelin, creating a complex regulatory network. The balance between apelin/APJ and angiotensin II/AT1R signaling is thought to be a key determinant of cardiovascular health.

Question 6

Does apelin have metabolic effects beyond cardiovascular function?

Accepted Answer

Yes. Apelin is expressed in adipose tissue (it is sometimes classified as an adipokine) and has significant metabolic effects. It enhances insulin sensitivity by promoting GLUT4 translocation to cell membranes, increases glucose uptake in skeletal muscle, and improves mitochondrial biogenesis. In animal models of obesity and type 2 diabetes, apelin administration improves glucose tolerance and reduces insulin resistance. Apelin also modulates food intake through hypothalamic circuits, though its role in appetite regulation is complex and context-dependent.

Question 7

What role does apelin play in angiogenesis?

Accepted Answer

Apelin is a potent angiogenic factor that promotes endothelial cell proliferation, migration, and tube formation. During embryonic development, the apelin/APJ axis is critical for normal vascular formation. In adults, apelin-driven angiogenesis is important for tissue repair and adaptation to ischemia. However, like other angiogenic factors, this property raises theoretical concerns about promoting tumor vascularization. The net effect of apelin on tumor biology is still debated, with some studies showing anti-tumor properties and others showing context-dependent pro-angiogenic effects.

Question 8

Is exogenous apelin safe?

Accepted Answer

Human safety data is limited to small acute infusion studies in heart failure patients, where apelin-13 and [Pyr1]apelin-13 were well tolerated with the primary observed effects being mild vasodilation and increased cardiac output. No serious adverse events were reported in these short-duration studies. The safety profile of chronic apelin administration in humans is unknown. Theoretical risks include excessive vasodilation (hypotension), fluid and electrolyte shifts from diuretic effects, and potential pro-angiogenic effects in individuals with occult malignancies.

Question 9

How does apelin affect fluid balance and blood pressure?

Accepted Answer

Apelin promotes aquaresis — the excretion of free water without proportional electrolyte loss — by opposing vasopressin's action at the kidney collecting duct. This makes apelin a potential treatment for conditions involving water retention, such as heart failure with hyponatremia. Regarding blood pressure, apelin causes vasodilation through endothelium-dependent nitric oxide release and direct smooth muscle relaxation. In normotensive subjects, the blood pressure reduction from acute apelin administration is modest, but in conditions with elevated vascular tone, the vasodilatory effect is more pronounced.

Question 10

Are there apelin-based drugs in clinical development?

Accepted Answer

Several pharmaceutical companies and academic groups have developed stabilized apelin analogs with extended half-lives for clinical investigation. These include analogs with non-natural amino acid substitutions, fatty acid conjugations, and cyclization strategies. Early-phase clinical trials have been conducted or are ongoing in heart failure, pulmonary arterial hypertension, and preeclampsia. However, no apelin-based therapeutic has advanced to Phase III trials or received regulatory approval as of the current evidence. The native apelin peptide itself is not a viable drug candidate due to its short half-life.

Question 11

How does exercise increase endogenous apelin release and what does this mean for cardiovascular health?

Accepted Answer

Exercise is one of the most potent physiological stimuli for apelin release, with both acute exercise bouts and chronic training programs significantly increasing circulating apelin levels. Skeletal muscle contraction directly stimulates apelin gene expression and secretion from myocytes, while exercise-induced improvements in insulin sensitivity further upregulate adipose tissue apelin production. Studies in both humans and rodents have demonstrated that the exercise-induced rise in apelin contributes to several cardiovascular adaptations: improved cardiac contractility, enhanced endothelial function through nitric oxide-mediated vasodilation, and beneficial cardiac remodeling that resists pathological hypertrophy. In aged mice, exercise-induced apelin restoration reversed age-related cardiac decline and improved muscle regenerative capacity. These findings suggest that apelin functions as an exercise-responsive myokine and that part of the well-established cardiovascular benefit of regular physical activity is mediated through the apelin/APJ axis.

Question 12

What is the relationship between apelin and ACE2, the enzyme involved in SARS-CoV-2 entry?

Accepted Answer

The relationship between apelin and ACE2 is bidirectional and clinically significant. ACE2 is the primary enzyme responsible for cleaving and inactivating apelin-13, meaning ACE2 activity directly regulates apelin bioavailability. Simultaneously, ACE2 is the cell-surface receptor that SARS-CoV-2 uses to enter host cells. During COVID-19 infection, viral binding to ACE2 downregulates its surface expression, which disrupts the normal degradation of apelin and also removes ACE2's protective role in converting angiotensin II to the vasodilatory angiotensin-(1-7). This creates a complex situation: reduced ACE2 activity may transiently increase apelin levels (less degradation) but simultaneously removes the cardiovascular protection provided by the ACE2/angiotensin-(1-7) pathway. The resulting imbalance — elevated angiotensin II, depleted angiotensin-(1-7), and disrupted apelin signaling — contributes to the cardiovascular complications observed in severe COVID-19, including myocarditis, thrombosis, and endothelial dysfunction.

Question 13

Could apelin supplementation benefit age-related cardiovascular decline?

Accepted Answer

There is compelling preclinical evidence that the apelin/APJ axis deteriorates with aging and that restoring apelin signaling reverses several hallmarks of cardiovascular aging. Circulating apelin levels decline significantly with age in both rodents and humans, and this decline correlates with reduced cardiac contractility, increased vascular stiffness, and impaired angiogenic capacity. In aged mice, chronic apelin infusion restored cardiac function, promoted new blood vessel formation in ischemic tissue, enhanced skeletal muscle regeneration, and even improved cognitive function through cerebrovascular improvements. A landmark 2018 study demonstrated that apelin functions as a key mediator of the anti-aging effects of exercise in aged animals, with APJ-knockout mice failing to benefit from exercise training. However, translating these findings to human therapy faces the challenge of apelin's short half-life, and it remains unknown whether chronic exogenous apelin in elderly humans would produce the same benefits seen in animal models or whether compensatory downregulation of APJ receptors would attenuate the response over time.

Origin / Manufacturer	Endogenous
Active Components	Apelin-13 or [Pyr1]apelin-13 peptideBacteriostatic water (for reconstitution)
Storage	Lyophilized: -20°C recommended. Reconstituted: 2–8°C
Shelf Life	Lyophilized 12–24 months at -20°C; reconstituted 14 days refrigerated
Form Factor	Lyophilized powder (1 mg vial)

Apelin

Specifications

Frequently Asked Questions

Related Peptides

Ac-SDKP (Thymosin Beta-4 Fragment)

Angiotensin-(1-7)

BPC-157

VIP (Vasoactive Intestinal Peptide)